{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:53:09Z","timestamp":1790484789843,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":869,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Institut de France \u2013 Fondation NRJ"},{"name":"MESR"},{"name":"MESR"},{"DOI":"10.13039\/501100001677","name":"Inserm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001677","name":"Inserm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UBO"},{"name":"CNRS"},{"DOI":"10.13039\/501100008222","name":"University of Montpellier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008222","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AFM-T\u00e9l\u00e9thon eOPMD","award":["17110"],"award-info":[{"award-number":["17110"]}]},{"name":"AFM-T\u00e9l\u00e9thon eOPMD","award":["17110"],"award-info":[{"award-number":["17110"]}]},{"DOI":"10.13039\/501100019125","name":"Sorbonne Universit\u00e9","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019125","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Association Institut de Myologie"},{"name":"DIM MALINF"},{"name":"INRAE"},{"name":"Fondation pour la Recherche Me\u0301dicale","award":["DEQ20150331689"],"award-info":[{"award-number":["DEQ20150331689"]}]},{"DOI":"10.13039\/501100004923","name":"AFM-T\u00e9l\u00e9thon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004923","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association D\u00e9fi Organisation"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-020-00992-6","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T14:35:40Z","timestamp":1612276540000},"page":"1137-1150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation"],"prefix":"10.1016","volume":"18","author":[{"given":"Aline","family":"Bamia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Sinane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Na\u00eft-Sa\u00efdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Dhiab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Keruzor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phu Hai","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Bertho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavie","family":"Soubigou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Halliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Capucine","family":"Trollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Simonelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Friocourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"B\u00e9ringue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bihel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7505-1927","authenticated-orcid":false,"given":"C\u00e9cile","family":"Voisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4542","key":"10.1007\/s13311-020-00992-6_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.6801762","article-title":"Novel proteinaceous infectious particles cause scrapie","volume":"216","author":"Prusiner","year":"1982","journal-title":"Science"},{"issue":"9","key":"10.1007\/s13311-020-00992-6_bib2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/nbt855","article-title":"Isolation of drugs active against mammalian prions using a yeast-based screening assay","volume":"21","author":"Bach","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-020-00992-6_bib3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejmech.2014.05.083","article-title":"Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles","volume":"82","author":"Nguyen","year":"2014","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10.1007\/s13311-020-00992-6_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/cn5001588","article-title":"Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost alpha2-adrenergic receptor agonistic activity","volume":"5","author":"Nguyen","year":"2014","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"10.1007\/s13311-020-00992-6_bib5","doi-asserted-by":"crossref","first-page":"e72112","DOI":"10.1371\/journal.pone.0072112","article-title":"The toll-like receptor agonist imiquimod is active against prions","volume":"8","author":"Oumata","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1007\/s13311-020-00992-6_bib6","doi-asserted-by":"crossref","first-page":"e1981","DOI":"10.1371\/journal.pone.0001981","article-title":"Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions","volume":"3","author":"Tribouillard-Tanvier","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1007\/s13311-020-00992-6_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1871526510909010031","article-title":"Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models","volume":"9","author":"Voisset","year":"2009","journal-title":"Infect Disord Drug Targets"},{"issue":"4","key":"10.1007\/s13311-020-00992-6_bib8","first-page":"435","article-title":"A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus","volume":"7","author":"Voisset","year":"2014","journal-title":"Dis Model Mech"},{"issue":"8","key":"10.1007\/s13311-020-00992-6_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/biot.200800134","article-title":"Tools for the study of ribosome-borne protein folding activity","volume":"3","author":"Voisset","year":"2008","journal-title":"Biotechnol J"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/19336896.2017.1303587","article-title":"The double life of the ribosome: When its protein folding activity supports prion propagation","volume":"11","author":"Voisset","year":"2017","journal-title":"Prion"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0167-4838(98)00179-4","article-title":"Protein folding in Escherichia coli: role of 23S ribosomal RNA","volume":"1429","author":"Chattopadhyay","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1007\/s13311-020-00992-6_bib12","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/biot.200800098","article-title":"Role of the ribosome in protein folding","volume":"3","author":"Das","year":"2008","journal-title":"Biotechnol J"},{"issue":"6062","key":"10.1007\/s13311-020-00992-6_bib13","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1126\/science.1212642","article-title":"The structure of the eukaryotic ribosome at 3.0 A resolution","volume":"334","author":"Ben-Shem","year":"2011","journal-title":"Science"},{"issue":"5","key":"10.1007\/s13311-020-00992-6_bib14","doi-asserted-by":"crossref","first-page":"e2174","DOI":"10.1371\/journal.pone.0002174","article-title":"Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs","volume":"3","author":"Tribouillard-Tanvier","year":"2008","journal-title":"PLoS One"},{"key":"10.1007\/s13311-020-00992-6_bib15","doi-asserted-by":"crossref","first-page":"32117","DOI":"10.1038\/srep32117","article-title":"Protein Folding Activity of the Ribosome is involved in Yeast Prion Propagation","volume":"6","author":"Blondel","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"10.1007\/s13311-020-00992-6_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41576-018-0011-4","article-title":"Prions, prionoids and protein misfolding disorders","volume":"19","author":"Scheckel","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"3","key":"10.1007\/s13311-020-00992-6_bib17","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/NEN.0b013e3182854c07","article-title":"Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients","volume":"72","author":"Gidaro","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1007\/s13311-020-00992-6_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00692226","article-title":"Nuclear inclusions in oculopharyngeal dystrophy","volume":"49","author":"Tome","year":"1980","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-020-00992-6_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng0298-164","article-title":"Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy","volume":"18","author":"Brais","year":"1998","journal-title":"Nat Genet"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng0298-164","article-title":"Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy","volume":"18","author":"Brais","year":"1998","journal-title":"Nat Genet"},{"issue":"4","key":"10.1007\/s13311-020-00992-6_bib21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1017\/S0317167100018588","article-title":"An 18 alanine repeat in a severe form of oculopharyngeal muscular dystrophy","volume":"41","author":"Jouan","year":"2014","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JND-140060","article-title":"PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling","volume":"2","author":"Richard","year":"2015","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1007\/s13311-020-00992-6_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/emmm.201000109","article-title":"Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy","volume":"3","author":"Barbezier","year":"2011","journal-title":"EMBO Mol Med"},{"key":"10.1007\/s13311-020-00992-6_bib24","doi-asserted-by":"crossref","unstructured":"Malerba A, Roth F, Harish P, et al. Pharmacological modulation of the ER stress response ameliorates oculopharyngeal muscular dystrophy. Hum Mol Genet 2019. https:\/\/doi.org\/10.1093\/hmg\/ddz007.","DOI":"10.1093\/hmg\/ddz007"},{"issue":"6","key":"10.1007\/s13311-020-00992-6_bib25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/jm030480f","article-title":"Selective optimization of side activities: another way for drug discovery","volume":"47","author":"Wermuth","year":"2004","journal-title":"J Med Chem"},{"issue":"19","key":"10.1007\/s13311-020-00992-6_bib26","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1359-6446(04)03213-1","article-title":"Multitargeted drugs: the end of the \"one-target-one-disease\" philosophy?","volume":"9","author":"Wermuth","year":"2004","journal-title":"Drug Discov Today"},{"issue":"Pt 6","key":"10.1007\/s13311-020-00992-6_bib27","doi-asserted-by":"crossref","first-page":"o681","DOI":"10.1107\/S1600536814010423","article-title":"Flunarizinium isonicotinate","volume":"70","author":"Kavitha","year":"2014","journal-title":"Acta Crystallogr Sect E Struct Rep Online"},{"issue":"1","key":"10.1007\/s13311-020-00992-6_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/JVI.78.1.482-490.2004","article-title":"Cultured peripheral neuroglial cells are highly permissive to sheep prion infection","volume":"78","author":"Archer","year":"2004","journal-title":"J Virol"},{"issue":"12","key":"10.1007\/s13311-020-00992-6_bib29","doi-asserted-by":"crossref","first-page":"11247","DOI":"10.1074\/jbc.M407006200","article-title":"Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells","volume":"280","author":"Feraudet","year":"2005","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1007\/s13311-020-00992-6_bib30","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1128\/JVI.75.13.5977-5984.2001","article-title":"Markedly increased susceptibility to natural sheep scrapie of transgenic mice expressing ovine prp","volume":"75","author":"Vilotte","year":"2001","journal-title":"J Virol"},{"issue":"44","key":"10.1007\/s13311-020-00992-6_bib31","doi-asserted-by":"crossref","first-page":"16031","DOI":"10.1073\/pnas.0502296102","article-title":"A newly identified type of scrapie agent can naturally infect sheep with resistant PrP genotypes","volume":"102","author":"Le Dur","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1007\/s13311-020-00992-6_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nbd.2010.09.010","article-title":"Marked influence of the route of infection on prion strain apparent phenotype in a scrapie transgenic mouse model","volume":"41","author":"Langevin","year":"2011","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-020-00992-6_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1471-2164-15-194","article-title":"Global transcript and phenotypic analysis of yeast cells expressing Ssa1, Ssa2, Ssa3 or Ssa4 as sole source of cytosolic Hsp70-Ssa chaperone activity","volume":"15","author":"Hasin","year":"2014","journal-title":"BMC Genomics"},{"issue":"6","key":"10.1007\/s13311-020-00992-6_bib34","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1016\/S0021-9258(17)41804-7","article-title":"Lindquist S. Saccharomyces cerevisiae Hsp104 protein. Purification and characterization of ATP-induced structural changes","volume":"269","author":"Parsell","year":"1994","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1007\/s13311-020-00992-6_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nprot.2008.13","article-title":"The prion organotypic slice culture assay--POSCA","volume":"3","author":"Falsig","year":"2008","journal-title":"Nat Protoc"},{"issue":"4","key":"10.1007\/s13311-020-00992-6_bib36","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ajpath.2011.06.044","article-title":"Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein","volume":"179","author":"Raz","year":"2011","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1007\/s13311-020-00992-6_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005092","article-title":"Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis","volume":"11","author":"Chartier","year":"2015","journal-title":"PLoS Genet"},{"issue":"Suppl 1","key":"10.1007\/s13311-020-00992-6_bib38","first-page":"S62","article-title":"Brain hypoxia in migraine: pathophysiologic and therapeutic implications","volume":"2","author":"Amery","year":"1982","journal-title":"J Cereb Blood Flow Metab"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1526-4610.1983.hed2302070.x","article-title":"Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine","volume":"23","author":"Amery","year":"1983","journal-title":"Headache"},{"issue":"5","key":"10.1007\/s13311-020-00992-6_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1528-1157.1985.tb05674.x","article-title":"Open dose-ranging trial of flunarizine as add-on therapy in epilepsy","volume":"26","author":"Binnie","year":"1985","journal-title":"Epilepsia"},{"issue":"1","key":"10.1007\/s13311-020-00992-6_bib41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-198427010-00002","article-title":"Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use","volume":"27","author":"Holmes","year":"1984","journal-title":"Drugs"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1523\/JNEUROSCI.22-02-00396.2002","article-title":"Differential inhibition of T-type calcium channels by neuroleptics","volume":"22","author":"Santi","year":"2002","journal-title":"J Neurosci"},{"issue":"17","key":"10.1007\/s13311-020-00992-6_bib43","doi-asserted-by":"crossref","first-page":"7044","DOI":"10.1073\/pnas.1303510110","article-title":"Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents","volume":"110","author":"Karapetyan","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1007\/s13311-020-00992-6_bib44","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1128\/JVI.77.19.10288-10294.2003","article-title":"New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products","volume":"77","author":"Kocisko","year":"2003","journal-title":"J Virol"},{"issue":"14","key":"10.1007\/s13311-020-00992-6_bib45","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1073\/pnas.1620400114","article-title":"Prion protein dynamics before aggregation","volume":"114","author":"Srivastava","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 8","key":"10.1007\/s13311-020-00992-6_bib46","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1099\/vir.0.80082-0","article-title":"Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice","volume":"85","author":"Kocisko","year":"2004","journal-title":"J Gen Virol"},{"issue":"8","key":"10.1007\/s13311-020-00992-6_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104287","article-title":"White blood cell-based detection of asymptomatic scrapie infection by ex vivo assays","volume":"9","author":"Halliez","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/jam.12055","article-title":"A subset of histamine receptor ligands improve thermotolerance of the yeast Saccharomyces cerevisiae","volume":"114","author":"Papamichael","year":"2013","journal-title":"J Appl Microbiol"},{"issue":"22","key":"10.1007\/s13311-020-00992-6_bib49","doi-asserted-by":"crossref","first-page":"10929","DOI":"10.1093\/nar\/gkw703","article-title":"Nuclear poly(A)-binding protein aggregates misplace a pre-mRNA outside of SC35 speckle causing its abnormal splicing","volume":"44","author":"Klein","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"10.1007\/s13311-020-00992-6_bib50","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1038\/sj.emboj.7601117","article-title":"A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1","volume":"25","author":"Chartier","year":"2006","journal-title":"EMBO J"},{"issue":"1","key":"10.1007\/s13311-020-00992-6_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2044-5040-1-15","article-title":"Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients","volume":"1","author":"Anvar","year":"2011","journal-title":"Skelet Muscle"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jsb.2012.05.002","article-title":"Chaperone networks in protein disaggregation and prion propagation","volume":"179","author":"Winkler","year":"2012","journal-title":"J Struct Biol"},{"issue":"4","key":"10.1007\/s13311-020-00992-6_bib53","first-page":"348","article-title":"Evaluation of memory-enhancing effect of flunarizine on active avoidance in experimental model of Alzheimer's disease through calcium homeostasis","volume":"13","author":"Kamili","year":"2019","journal-title":"Int J Green Pharm"},{"issue":"1","key":"10.1007\/s13311-020-00992-6_bib54","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s41598-018-20219-1","article-title":"Small-molecule flunarizine increases SMN protein in nuclear Cajal bodies and motor function in a mouse model of spinal muscular atrophy","volume":"8","author":"Sapaly","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1007\/s13311-020-00992-6_bib55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10545-016-9986-1","article-title":"Flunarizine rescues reduced lifespan in CLN3 triple knock-out Caenorhabditis elegans model of batten disease","volume":"40","author":"Kwon","year":"2017","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"10.1007\/s13311-020-00992-6_bib56","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nchembio.79","article-title":"Novel targets for Huntington's disease in an mTOR-independent autophagy pathway","volume":"4","author":"Williams","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"48","key":"10.1007\/s13311-020-00992-6_bib57","doi-asserted-by":"crossref","first-page":"19023","DOI":"10.1073\/pnas.0709695104","article-title":"Small molecule regulators of autophagy identified by an image-based high-throughput screen","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00992-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00992-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00992-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:51:57Z","timestamp":1761807117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1878747923011534"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00992-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00992-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}